ATYR
HealthcareaTyr Pharma, Inc.
$0.75
$-0.01 (-1.71%)
Jan 5, 2026
Price History (1Y)
Analysis
aTyr Pharma, Inc. is a biotechnology company in the healthcare sector with a market capitalization of $73.10 million and 56 employees. The company's revenue for the trailing twelve months (TTM) was $190,000. The financial health of aTyr Pharma is characterized by significant net losses, as evident from its TTM net income of -$75,122,000. The company also reported EBITDA and free cash flow deficits of -$77,978,000 and -$34,649,876, respectively. However, the company maintains a substantial cash balance of $90.20 million and relatively low debt of $12.36 million. The valuation context for aTyr Pharma is marked by a negative forward P/E ratio of -1.41, which may indicate expectations for future losses or slow revenue growth. The price to book ratio stands at 0.91, while the price to sales ratio is significantly high at 384.73. The company's debt to equity ratio is 15.44, and its current ratio is 5.93.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About aTyr Pharma, Inc.
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; and in Phase 1b/2a clinical trial to treat other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Visit website →Key Statistics
- Market Cap
- $73.10M
- P/E Ratio
- N/A
- 52-Week High
- $7.29
- 52-Week Low
- $0.64
- Avg Volume
- 4.12M
- Beta
- 0.60
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 56